26/10/2026
ADVANCING API EXCELLENCE. STRENGTHENING GLOBAL CAPABILITIES.
Globela Industries’ API Plant has achieved a significant regulatory milestone with 7 USDMF approvals.
This achievement reflects our continued focus on pharmaceutical quality, regulatory compliance, and strengthening our capabilities to support global pharmaceutical markets.
The approved products include Artemether USP, Lumefantrine USP, Acyclovir USP, Febuxostat, Deferasirox, Ofloxacin USP, and Apixaban USP.
We appreciate the dedication and expertise of our team in contributing to this achievement as we continue to build strong pharmaceutical partnerships worldwide.
Globela Pharma
Every Life Is Precious.